Physician profile

David A Marks

Pulmonary Disease · San Antonio, TX

NPI 1821016023

$452,503.53

in general payments reported to CMS, 2019-2025

58 companies · $107K in 2025

The $107K reported for 2025 was more than what 99% of Pulmonary Disease providers received nationally (typical 2025 total: $500).

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program$302,300.00
Travel and Lodging$40,399.59
Food and Beverage$14,802.09
Education$5,771.08

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Astrazeneca Pharmaceuticals Lp $392,370.88 2019-2025 Airsupra, Breztri, Fasenra
Glaxosmithkline, LLC. $35,528.28 2019-2025 Trelegy Ellipta, Nucala, Arexvy
Intuitive Surgical, INC. $6,942.18 2024-2025
Inspire Medical Systems, INC. $4,929.44 2024-2025 Inspire
Mallinckrodt Hospital Products INC. $2,819.20 2020-2025 Acthar
Bayer Healthcare Pharmaceuticals INC. $1,204.85 2019-2025
Actelion Pharmaceuticals US, INC. $1,019.28 2019-2024 Opsumit, Uptravi
Boehringer Ingelheim Pharmaceuticals, INC. $962.04 2019-2025 Ofev, Jascayd
Pulmonx Corporation $878.52 2019-2024 Chartis Catheter, Zephyr Delivery Catheter, Zephyr Endobronchial Valve
Hill-Rom Company, INC $875.00 2021
Grifols USA, LLC $632.00 2019-2025 Prolastin-C Liquid, Xembify
Regeneron Healthcare Solutions, INC. $588.95 2019-2025 Dupixent
Merz North America, INC. $296.09 2023
Jazz Pharmaceuticals INC. $266.51 2019-2025
Mylan Specialty L.P. $229.82 2019-2022
Show all 51 companies
CompanyGeneral paymentsYearsTop products
Takeda Pharmaceuticals U.S.A., INC. $217.97 2021-2024 Glassia
Shire North American Group INC $185.86 2019
Axsome Therapeutics, INC. $176.83 2024-2025 Sunosi
Electromed, INC. $174.29 2019-2025 Smartvest
Zoll Respicardia, INC. $161.37 2024 Remede System
Genzyme Corporation $145.13 2019-2025
United Therapeutics Corporation $143.48 2019-2025 Tyvaso, Tyvaso
Organogenesis INC. $130.13 2022-2023 Puraply
Harmony Biosciences LLC $125.21 2021-2025
Verona Pharma, INC. $124.98 2025 Ohtuvayre
Phadia US INC. $116.02 2024-2025 Immunocap
Insmed, INC. $115.04 2019-2025 Arikayce, Brinsupri
Vifor Pharma, INC. $114.35 2024 Zemaira, Veltassa
Biofire Diagnostics, LLC $90.01 2019
Baxter Healthcare $87.26 2022-2025 Hillrom - Vest System Model 105 Home Care, Hillrom - Life 2000 Ventilation System
Ani Pharmaceuticals, INC. $86.54 2024-2025 Purified Cortrophin Gel
Tactile Systems Technology INC $85.31 2024-2025 Flexitouch Plus, Entre Plus, Nimbl
Janssen Pharmaceuticals, INC $70.23 2019-2021
Fisher & Paykel Healthcare INC $66.79 2024 Fisher & Paykel Healthcare
Philips North America LLC $61.97 2019-2022
Sunovion Pharmaceuticals INC. $60.12 2019
Advanced Respiratory, INC $54.39 2020
Amgen INC. $49.93 2024 Tezspire
Viatris Specialty LLC $39.03 2025 Yupelri
Paratek Pharmaceuticals, INC. $38.98 2021-2022
Circassia INC. $35.78 2019-2024 Niox
Genentech USA, INC. $34.40 2019-2022
Merck Sharp & Dohme LLC $29.36 2024 Winrevair
Novartis Pharmaceuticals Corporation $23.31 2019
Gilead Sciences, INC. $21.44 2019
Itamar Medical INC $21.04 2022
Idorsia Pharmaceuticals US INC $19.83 2024 Quviviq
Optinose US, INC. $15.34 2019
Pharming Healthcare, INC. $13.62 2025 Ruconest
Boston Scientific Corporation $12.79 2019
Apria Healthcare LLC $12.36 2021

7 companies reported research payments only; those appear in the research section below.

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

David A Marks

$452,503.53

in general payments reported 2019-2025

Years
2019-2025
Top company
Astrazeneca Pharmaceuticals Lp
Context
The $107K reported for 2025 was more than what 99% of Pulmonary Disease providers received nationally (typical 2025 total: $500).

https://glasscript.com/doctor/81974/david-a-marks

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.